Previous 10 | Next 10 |
Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizin...
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System PR Newswire NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model ...
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of...
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire AUSTIN, Texas , March 22, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene ther...
2024-03-20 10:13:02 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in li...
A look at the top 10 most actives in the United States Fisker Inc. Class A (FSR) fell 9.8% to $0.133 on volume of 209,262,975 shares Ontrak Inc. (OTRK) rose 131.6% to $0.44 on volume of 206,699,914 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 1.7% to $3.65 on volume of 1...
Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded wa...
2024-03-19 08:48:58 ET More on Genprex Genprex to effect 1-for-40 reverse stock split to regain Nasdaq compliance Seeking Alpha’s Quant Rating on Genprex Financial information for Genprex Read the full article on Seeking Alpha For further detai...
News, Short Squeeze, Breakout and More Instantly...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Suppor...